Medical technology company Stryker (NYSE:SYK) reported in Q4 CY2024, with sales up 10.7% year on year to $6.44 billion. Its ...

Learn more about whether Edwards Lifesciences Corporation or Stryker Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

(d) Charges represent the costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device reporting regulations and ...

Capital Spending Guidance for 2025: $800 million to $850 million. Stryker Corp (NYSE:SYK) reported impressive organic sales growth exceeding 10% for both Q4 and the full year 2024. The company ...

Medical device maker Stryker Corporation (SYK) benefits from more procedures, sales, and acquisitions.

Stryker Corporation (SYK)'s share was trading at ... In 2023, Stryker generated $20.50 billion in net sales, a remarkable 11% increase from the previous year, driven by its two main business ...

Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2024: Fourth Quarter Results Reported net sales increased 10.7% ...

In a remarkably news-filled earnings call on Jan. 28, Stryker Corp. revealed plans to sell its U.S. and spinal implants business to Viscogliosi Brothers LLC for an undisclosed sum, announced the ...

Medical technology company Stryker (NYSE:SYK) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 10.7 ... Stryker Corporation today designs and sells a wide range ...

2025 Guidance for Organic Sales Growth: 8% to 9%. 2025 Adjusted EPS Guidance: $13.45 to $13.70 per share. Cash and Marketable Securities: $4.5 billion at year-end. Total Debt: Approximately $13.6 ...